GLP-1 Receptor Agonists and the Kidney: Progress With Important Caveats

Q: What is the clinical evidence from this study?

Study design: Editorial. Population: Type 2 diabetes. Intervention: GLP-1 receptor agonists vs. Dipeptidyl peptidase 4 inhibitors, SGLT-2 inhibitors, basal insulin, and non-GLP-1RA therapies. Primary outcome: Incident chronic kidney disease and composite kidney outcomes.

Setor K. Kunutsor; Jari A. Laukkanen

doi:10.1016/j.mayocp.2026.04.010

June 1, 2026Mayo Clinic ProceedingsOpen Access

GLP-1 Receptor Agonists and the Kidney: Progress With Important Caveats

View Full Paper

Ask AI

Bookmark

Share

Key result

GLP-1 receptor agonists were associated with lower risks of incident chronic kidney disease compared with DPP-4 inhibitors, but higher risks compared with SGLT-2 inhibitors in patients with type 2 diabetes.

Why the study?

Does initiation of GLP-1RAs reduce the risk of incident CKD and cardiovascular events compared with alternative glucose-lowering therapies in patients with T2D and no preexisting CKD?

Structured PICO

Does initiation of GLP-1RAs reduce the risk of incident CKD and cardiovascular events compared with alternative glucose-lowering therapies in patients with T2D and no preexisting CKD?

P

Population

Patients with type 2 diabetes and no preexisting chronic kidney disease (as discussed in the referenced study by Yen et al.)

I

Intervention

GLP-1 receptor agonists

C

Comparator

Alternative glucose-lowering therapies including dipeptidyl peptidase 4 inhibitors, SGLT-2 inhibitors, basal insulin, and non-GLP-1RA therapies

O

Outcome

Incident CKD, kidney failure, cardiovascular events, and mortality

Limitations

TriNetX data lack detailed information on drug dose, duration, and adherence
Absence of dose-response analyses precludes evaluation of whether greater cumulative exposure confers stronger kidney protection
Follow-up duration may be insufficient to fully capture CKD development
Possibility of type I error due to multiplicity as multiple comparisons without formal multiplicity adjustment can inflate the risk of false-positive findings
Residual confounding and channeling bias cannot be excluded
absence of dose-response analyses
follow-up duration may be insufficient to fully capture CKD development
multiple target trial emulations raise the possibility of type I error due to multiplicity

Implication

This editorial reinforces that while GLP-1RAs provide cardiovascular benefits, SGLT-2 inhibitors remain the first-line agents for kidney protection in patients with type 2 diabetes.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kunutsor et al. (2026) conducted an editorial in Type 2 diabetes. GLP-1 receptor agonists vs. Dipeptidyl peptidase 4 inhibitors, SGLT-2 inhibitors, basal insulin, and non-GLP-1RA therapies was evaluated on Incident chronic kidney disease and composite kidney outcomes. GLP-1 receptor agonists were associated with lower risks of incident chronic kidney disease compared with DPP-4 inhibitors, but higher risks compared with SGLT-2 inhibitors in patients with type 2 diabetes.

synapsesocial.com/papers/6a3c235fd15afadd906fa0f0 https://doi.org/10.1016/j.mayocp.2026.04.010

View Full Paper

Ask AI

Bookmark

Share

GLP-1 Receptor Agonists and the Kidney: Progress With Important Caveats

Structured PICO

Limitations

Implication

Abstract

Discussion

Cite This Study

GLP-1 Receptor Agonists and the Kidney: Progress With Important Caveats

Structured PICO

Limitations

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Mayo Clinic Proceedings

Keep reading

More related papers

More from Mayo Clinic Proceedings